IceCure Medical (NASDAQ:ICCM – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $3.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 308.16% from the stock’s current price.
Separately, Alliance Global Partners boosted their price objective on IceCure Medical from $1.90 to $2.90 and gave the company a “buy” rating in a research note on Wednesday, March 20th.
View Our Latest Research Report on IceCure Medical
IceCure Medical Stock Performance
IceCure Medical (NASDAQ:ICCM – Get Free Report) last posted its quarterly earnings results on Tuesday, May 28th. The company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. The company had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.80 million. During the same quarter in the previous year, the firm posted ($0.08) EPS. On average, research analysts predict that IceCure Medical will post -0.28 EPS for the current year.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Featured Stories
- Five stocks we like better than IceCure Medical
- What to Know About Investing in Penny Stocks
- Snowflake Stock Rebounds, Flies Higher on AI Spending
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.